Jacobio Pharmaceuticals Group Co Ltd banner

Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167

Watchlist Manager
Jacobio Pharmaceuticals Group Co Ltd Logo
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Watchlist
Price: 8.2 HKD 2.5% Market Closed
Market Cap: HK$6.4B

Jacobio Pharmaceuticals Group Co Ltd
Investor Relations

Jacobio Pharmaceuticals Group Co., Ltd. operates as an investment holding company which engages in research and development of new drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-12-21. The firm is primarily responsible for the independent discovery and development of innovative tumor therapies. The firm's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The firm mainly conducts business within the domestic market.

Show more
Loading
1167
Hang Seng (Hong Kong)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Yinxiang Wang
Executive Chairman & CEO
No Bio Available
Ms. Xiaojie Wang
Executive Director & President of Administration
No Bio Available
Ms. Yunyan Hu
Executive VP & Executive Director
No Bio Available
Ms. Tao Yang
Vice President of Human Resources
No Bio Available
Dr. Andrea Wang-Gillam M.D., Ph.D.
Executive VP, Chief Medical Officer and Global Head of R&D
No Bio Available
Ms. Yanping Wang
Executive Vice President of Non-Clinical R&D
No Bio Available
Dr. Haijun Wang
Senior Vice President of Information & Data Management
No Bio Available
Ms. Yuli Ding
Executive Vice President of Clinical Development
No Bio Available
Mr. Ming Fai Chung CPA
Joint Company Secretary
No Bio Available

Contacts

Address
BEIJING
Beijing
Building F2, No. 88, Kechuang 6th Street, Beijing Economic-Technological Development Area
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett